孟鲁司特片联合玉屏风颗粒治疗过敏性紫癜的临床研究

发布时间：2018-06-28 19:55

本文选题：孟鲁司特 + 玉屏风颗粒　；参考：《中国临床药理学杂志》2017年17期

【摘要】：目的观察孟鲁司特片联合玉屏风颗粒治疗儿童过敏性紫癜的临床疗效及安全性。方法将130例过敏性紫癜患儿随机分为对照组65例和试验组65例。对照组予以口服孟鲁司特,3~4岁4 mg·d~(-1),6岁以上5 mg·d~(-1),每晚睡前给药一次;试验组在对照组治疗的基础上,予以口服玉屏风颗粒,3~7岁每次2.5 g,7~14岁每次5 g,tid。2组患者均治疗3个月。比较2组患儿的临床疗效、复发率,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为93.84%(61/65例)和75.38%(49/65例),复发率分别为0(0/65例)和15.38%(10/65例),差异均有统计学意义(均P0.05)。试验组发生的药物不良反应主要有头晕、腹泻、发热,对照组发生的药物不良反应主要有发热、恶心、头晕、胸闷。试验组和对照组的药物不良反应发生率分别为6.15%和7.69%,差异无统计学意义(P0.05)。结论孟鲁司特片联合玉屏风颗粒治疗儿童过敏性紫癜的临床疗效确切,且不增加药物不良反应的发生率。
[Abstract]:Objective to observe the efficacy and safety of montelukast combined with Yupingfeng granule in the treatment of allergic purpura in children. Methods 130 children with Henoch-Schonlein purpura were randomly divided into control group (n = 65) and experimental group (n = 65). The control group was treated with oral montelukast 3 years 4 years old 4 mg d ~ (-1), 5 mg d ~ (-1) every night before bedtime, and the experimental group was treated for 3 months with 5 g / d ~ (-2) of 5 g / d ~ (-1) at the age of 2. 5 g / time, 7 years old and 7 years old, on the basis of the treatment in the control group. The clinical efficacy, recurrence rate and adverse drug reaction were compared between the two groups. Results after treatment, the total effective rates were 93.84% (61 / 65 cases) and 75.38% (49 / 65 cases), respectively, and the recurrence rates were 0 (0 / 65 cases) and 15.38% (10 / 65 cases) in the experimental group and the control group, respectively (P0.05). The main adverse drug reactions in the test group were dizziness, diarrhea and fever, while in the control group there were fever, nausea, dizziness and chest tightness. The incidence of adverse drug reactions in the test group and control group was 6.15% and 7.69% respectively, the difference was not statistically significant (P0.05). Conclusion Montelukast tablet combined with Yupingfeng granule is effective in the treatment of children with Henoch-Schonlein purpura and does not increase the incidence of adverse drug reactions.
【作者单位】：济南市儿童医院皮肤科;
【基金】：国家医学教育发展中心医学研究课题基金资助项目(2010-13-01-064)
【分类号】：R725.5

【相似文献】